Preregistration

Registered Clinical Trials Investigating 3,4-Methylenedioxymethamphetamine (MDMA) For Psychiatric Disorders

OSFFeb 22, 2022

Abstract

Modified systematic review.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

MDMADepressionPTSDAnxiety

Keywords

3,4-MethylenedioxymethamphetamineAnxiety disorderattention-deficit hyperactivity disorderautism spectrum disorderBipolar Disordercognitive impairmentdelusional disorderMajor Depressive DisorderObsessive Compulsive Disorderpersonality disorderpost-traumatic stress disorderschizoaffective disorderschizophreniaSuicideTrauma

View preregistration

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Portes MAM, Bertoglio LJ

Europe PMC2026

PreprintKetamine

Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)

Braxton AM, Driver C, Hermens DF +1